Comparison between the first-line and second-line immunotherapy drugs in the progression-free survival and overall survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials | Zendy

Shengyu Wu | Zendy; Lei Wang | Zendy; Wei Li | Zendy; Bin Chen | Zendy; Yu Liu | Zendy; Hao Wang | Zendy; Sha Zhao | Zendy; Lingyun Ye | Zendy; Hui Sun | Zendy; Yayi He | Zendy

Open Access

Comparison between the first-line and second-line immunotherapy drugs in the progression-free survival and overall survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

Author(s) -

Shengyu Wu,

Lei Wang,

Wei Li,

Bin Chen,

Yu Liu,

Hao Wang,

Sha Zhao,

Lingyun Ye,

Hui Sun,

Yayi He

Publication year - 2020

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-20-449

Subject(s) - medicine , immunotherapy , lung cancer , hazard ratio , oncology , meta analysis , confidence interval , randomized controlled trial , clinical trial , cancer

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer but with a low early diagnosis rate. With immunotherapy becomes popular in lung cancer, single immunotherapy drug treatment as the first-line or second-line plays an important role. The meta-analysis compares different clinical effects of them by overall survival (OS) and progression-free survival (PFS) because it is important to detect the best time of immunotherapy for NSCLC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research